Warning letter · FDA Warning Letters, Historical Archive

BrainAlert, LLC: FDA Warning Letter (Dec 14, 2017)

Agency action: Dec 14, 2017Record ID: fda_warning_-6cc5825abf7a51c2
View official source ↗

What happened

Original notice title

BrainAlert, LLC 12/14/17

From the archived source record

The inspection revealed serious violations of the Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements regulation, Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause your BrainAlert product to be adulterated within the meaning of section 402(g)(1) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(g)(1)] in that it has been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements. Based on our review, we have concluded that your BrainAlert product is an unapproved new drug and misbranded drug and that, even if it were not a drug, it would be a misbranded dietary supplement, as explained further below. Unapproved New Drugs/Misbranded Drugs FDA reviewed your website www.brainalert.com in August 2017 and again in December 2017 and determined that you take orders there for your product BrainAlert. The following are examples of citations as listed on your website used to market BrainAlert for disease treatment and prevention and are thus evidence of your product’s intended use as a drug: “Schonheit K, Gille L, Nohl H, Institute of Pharmacology and Toxicology, Veterinary University of Vienna, Austria. Huperzine A, a potential therapeutic agent for dementia, reduces neuronal cell death caused by glutamate. Psychopharmacol Bull 1982;18:7-18.” “Yun TK, Choi SY. A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). Accordingly, BrainAlert fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. § 331(a)].

What the official notice says to do

Check the original notice for the instructions that apply to the named product, company, and affected lots.

Read the official notice →

Status and source details

Status recorded in the archive
Historical warning letter; closeout not established by annual index
Source checked
Jul 16, 2026
Record revision
f7df0b8dd392

This is a dated record. Its current status may have changed since the source was captured. A record applies to its stated scope; it is not a safety rating for every product from a company.

Sources, dates, and coverage →

What is affected

Product
BrainAlert; for distribution [72 Fed
Company
BrainAlert, LLC
Lot / identifier
The source does not specify this field.
Market / distribution
The source does not specify this field.